Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 10/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27949767 | 0.88 | ARF6 (0.47) | ARF6CYP3A4DPP4KDM4EKMT2A | |
| SCHEMBL10275796 | 0.87 | CYP3A4 (0.41) | ARF6CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL10275917 | 0.86 | ARF6 (0.50) | ARF6PLATCNR1CNR2 | |
| SCHEMBL10275511 | 0.85 | ARF6 (0.43) | ARF6CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL10275156 | 0.84 | ARF6 (0.45) | ARF6PLATKDM1A | |
| SCHEMBL10276119 | 0.84 | ARF6 (0.42) | ARF6CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL10276039 | 0.83 | ARF6 (0.41) | ARF6CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL10275640 | 0.83 | ARF6 (0.53) | ARF6CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL10276011 | 0.81 | ARF6 (0.41) | ARF6 | |
| SCHEMBL10275181 | 0.78 | MEN1 (0.38) | ARF6CYP3A4DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | ARF6 3355/4885CYP3A4 33/4885DPP4 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.